We came across a bullish thesis on BioNTech SE on Memyselfandi007’s Substack. In this article, we will summarize the bulls’ thesis on BNTX. BioNTech SE’s share was trading at $103.80 as of March 4th.

The biotech continues to embrace artificial intelligence (AI) technology, which is heartening for investors. It owns and manages an AI developer, InstaDeep. Showing their approval, those market ...

In recent months, BioNTech has moved further beyond its COVID-19 roots by acquiring Chinese startup Biotheseus and inking a major Bristol Myers partnership around oncology candidate BNT327, which ...

Investors are bracing for a pivotal week for BioNTech SE, as the biotech firm prepares to release its full-year 2025 and fourth-quarter results. The upcoming re ...

BioNTech SE reports fourth-quarter and full-year 2025 results Tuesday before the market opens, confronting investors with a stark contrast: plunging COVID-19 vaccine sales against ambitious oncology ...

Investors are bracing for a pivotal moment for BioNTech SE. The German biotechnology firm is set to release its full-year 2025 financial results on March 10, an ...

People aiming to get its Comirnaty Covid vaccine won't need a doctor's prescription to do so. This was among several measures being considered by an advisory panel to the CDC. Investors were cheered ...

BioNTech SE (NASDAQ:BNTX) is one of the best stocks to buy and hold for the next 6 months. On February 2, research firm Leerink Partners downgraded BioNTech SE (NASDAQ:BNTX) to a Market Perform from ...

In a separate but significant development, BioNTech's legal dispute with Moderna has entered a new phase. The company has sued its U.S. competitor in a federal court in Delaware, alleging that Moderna ...

BioNTech SE is transitioning from a COVID-19 vaccine story to a late-stage oncology platform with a robust $17B cash position. Click to read why BNTX is a Buy.

BioNTech SE Sponsored ADR (BNTX) shares rallied 11.8% in the last trading session to close at $118. This move can be attributable to notable volume with a higher number of shares being traded than in ...